RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.Why do you think Matt would state in his most recent podcast. that the mBC trial would require 400-500 patients... THIS is exactly the number that was posited to investors 5 years ago, when ONCY recieved a SPA from FDA...
Matt was then telling us that with biomarkers, they could get the population down to 250, and thus save time..
SO.. 5 years on, we have the same trial size... still no partner to pay for the trial, and how much have we been diluted since then. had ONCY started its Phase III back in 2018 with Pela + Pax, then we would soon be getting ready to file a BLA...
This is not going anywhere, because the distinction between OS from Pela+Pax compared to Pela + Pax + CPI won't be evident until next year... My gues is NO partnership this year, instead they will go it alone with just Pela + Pax..
But of course... we shall see won't we... and not much longer to wait until your fantasy world is exposed for what it is, blatant pumping...